BridgeBio Pharma, Inc. (BBIO) fair value analysis
Nasdaq · Updated 2026-10-19
BBIO price how computed
Valuation status
No fair-value estimate yetBBIO has no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for our trailing P/E history.
Forward Fair Value needs both, so TickrTrends publishes no verdict for BBIO yet. We re-check every week; the price, fundamentals, technicals and earnings data below are unaffected.
- Last price
- $66.39
- Sector
- Healthcare
- 12-month range
- $53.81–$90.17
- Market cap
- $13B
- From 52-week high
- -26.4%
- Shares outstanding
- 195M
- Rank in Healthcare by quality score
- #133 of 301
Last price is the 2026-10-16 close; the chart runs through 2026-10-16.
BridgeBio Pharma, Inc. is a clinical-stage biopharmaceutical company that develops and seeks to commercialize novel medicines targeting genetic diseases and cancers. The company operates in the United States and internationally, focusing on advancing its pipeline of investigational therapeutics through clinical development.
BBIO currently ranks #133 of 301 Healthcare stocks by quality score.
Fundamentals (4 quarters) how computed
- Market cap
- $13B
- P/E (trailing)
- n/m
- Revenue (TTM)
- $692M
- Net margin
- -100.6%
- EPS (TTM)
- $-3.28
- Gross margin
- 93.2%
- Debt / equity
- 0.00
- Revenue growth (3-yr avg)
- 1779.1%
- Shares outstanding
- 195M
Derived indicators how computed
- Quality grade
- D
- Margin trend
- Expanding
- 52-week position
- The lower-middle quarter of its range
Technicals how computed
- RSI (14-day)
- 49 · neutral
- 50-day average
- $72.94
- 200-day average
- $73.08
- Moving-average state
- 50-day below 200-day (death cross state); price below both averages
Earnings how computed
- Next earnings report
- 2026-11-04
- Last 8 quarters vs consensus
- 2 beat, 6 missed
- Quarter by quarter
- 2026-06 ▼ miss (-21.9%)
2026-03 ▼ miss (-35.5%)
2025-12 ▼ miss (-31.1%)
2025-09 ▲ beat (+7.7%)
2025-06 ▼ miss (-58.3%)
2025-03 ▼ miss (-11.1%)
2024-12 ▼ miss (-26.1%)
2024-09 ▲ beat (+12.3%)
Analyst consensus how computed
This is not TickrTrends' verdict.
- Analyst ratings
- 19 buy · 3 hold · 0 sell (22 analysts)
- Consensus lean
- Buy-leaning
- Consensus price target
- $108
- Target vs last price
- +62.7%
What our data shows for BBIO
- Shares are trading in the middle of their 12-month price range of $53.81–$90.17.
- The 14-day relative strength index sits at a neutral 49.
What subscribers see
- Every published Forward Fair Value with its exact discount or premium
- The normalized P/E and quarter count behind each estimate
- Screeners and rankings across the full S&P 500 and Nasdaq universes
- BBIO's own verdict the week it qualifies, published automatically
Forward Fair Value applies a conservatively normalized historical price-to-earnings multiple to the consensus earnings estimate for the next full fiscal year; how TickrTrends computes it.
What people are saying
Follow the BBIO conversation: Stocktwits · Reddit · X
TickrTrends weekly updates
- 2026-10-19 — TickrTrends' derived indicators for BBIO show a shift in trend momentum this week. The 50/200-day trend state has moved from mixed to downtrend, reflecting a change in the Healthcare sector company's recent price movement patterns. The current valuation verdict for BBIO remains awaiting full valuation.
- 2026-10-12 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-11 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-10 — TickrTrends' derived indicators for BBIO showed a shift this week, with the Relative Strength Index moving from an oversold zone into neutral territory. The Healthcare sector company remains under full valuation review with no current verdict issued. This technical adjustment reflects changing momentum conditions in the stock's recent trading activity.
- 2026-10-06 — No material change this week: the verdict, bands and grades all held steady.
- 2026-10-05 — No material change this week: the verdict, bands and grades all held steady.
- 2026-09-28 — TickrTrends' derived indicators for BBIO show notable shifts this week. The gross-margin trend has moved from none to expanding, suggesting improving profitability metrics, while the Relative Strength Index zone has transitioned from neutral to oversold territory. The stock's current valuation verdict remains awaiting full valuation.
- 2026-09-06 — TickrTrends initiated weekly Forward Fair Value coverage of this stock.
Frequently asked questions
Is BBIO stock undervalued?
TickrTrends has no fair-value estimate for BBIO yet: there is no usable analyst consensus for next fiscal year's earnings, or too few reported quarters for a trailing P/E history. It is re-checked every week.
What is BBIO's TickrTrends verdict?
BBIO is currently marked 'No fair-value estimate yet' - a verdict publishes automatically once a forward earnings consensus and enough reported quarters are available.
How does BBIO compare to other Healthcare stocks?
BBIO ranks #133 of 301 Healthcare stocks in TickrTrends' coverage by quality score. It carries no fair-value verdict yet, so it is not ranked by discount.
Is BBIO overbought or oversold?
BBIO's 14-day RSI is in neutral territory - neither overbought nor oversold.
When does BBIO report earnings next?
BBIO's next earnings report is scheduled for 2026-11-04, per the published earnings calendar.
Does BBIO usually beat earnings estimates?
Over its last 8 reported quarters BBIO beat the consensus estimate 2 times and missed 6 times, by TickrTrends' comparison of reported and estimated EPS.
What do analysts say about BBIO?
Of 22 analysts covering BBIO, 19 rate it a buy, 3 a hold and 0 a sell - buy-leaning, with a consensus price target of $108 (+62.7% versus TickrTrends' last price). This is the analyst consensus, not TickrTrends' Forward Fair Value verdict.